Rheumatoid vasculitis treated with infliximab.
We describe a patient with rheumatoid vasculitis (RV) who showed a good response to anti-tumor necrosis factor-a therapy. TNF-a antagonists should be considered as treatment in systemic RV, especially in patients who do not respond to immunosuppressive drugs or who have contraindication for such treatment.
van der Bijl
A Egon
AE
Department of Rheumatology, Leiden University Medical Centre, The Netherlands. a.e.van_der_bijl@lumc.nl
Allaart
Cornelia F
CF
Van Vugt
Jeroen
J
Van Duinen
Sjoerd
S
Breedveld
Ferdinand C
FC
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D012216:Rheumatic Diseases / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014657:Vasculitis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab